Smith & Nephew plc (LON:SN)
London · Delayed Price · Currency is GBP · Price in GBp | Market Cap | 11.62B |
| Revenue (ttm) | 4.33B |
| Net Income (ttm) | 358.03M |
| Shares Out | 859.11M |
| EPS (ttm) | 0.41 |
| PE Ratio | 33.24 |
| Forward PE | 17.02 |
| Dividend | 0.28 (2.09%) |
| Ex-Dividend Date | Oct 2, 2025 |
| Volume | 3,328,125 |
| Average Volume | 4,334,448 |
| Open | 1,357.50 |
| Previous Close | 1,353.00 |
| Day's Range | 1,349.00 - 1,364.00 |
| 52-Week Range | 911.00 - 1,441.50 |
| Beta | 0.67 |
| RSI | 50.27 |
| Earnings Date | Oct 30, 2025 |
About Smith & Nephew
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. It operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction proced... [Read more]
Financial Performance
In 2024, Smith & Nephew's revenue was $5.81 billion, an increase of 4.70% compared to the previous year's $5.55 billion. Earnings were $412.00 million, an increase of 56.65%.
Financial numbers in USD Financial StatementsNews
Smith+Nephew announce latest scientific data supporting new ALLEVYN™ COMPLETE CARE 5-Layer Foam Dressing for pressure injury prevention
Smith+Nephew (NYSE:SNN; LSE:SN), the global medical technology business, is pleased to announce exciting new data from Professor Amit Gefen and his research group published in the International Wound ...
Smith+Nephew launches CORIOGRAPH™ Pre-Op Planning and Modeling Services for total shoulder arthroplasty
Completes the CORIOGRAPH Services portfolio which also includes solutions for knee and hip arthroplasty Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the laun...
Ex-Dividend Reminder: ESAB, Sylvamo and Smith & Nephew
Looking at the universe of stocks we cover at Dividend Channel, on 10/3/25, ESAB Corp (Symbol: ESAB), Sylvamo Corp (Symbol: SLVM), and Smith & Nephew plc (Symbol: SNN) will all trade ex-dividend for t...
Smith & Nephew Reaches Analyst Target Price
In recent trading, shares of Smith & Nephew plc (Symbol: SNN) have crossed above the average analyst 12-month target price of $35.55, changing hands for $36.29/share. When a stock reaches the target a...
Smith & Nephew (SNN) CFO Relocates to U.S. to Drive Growth
Smith & Nephew (SNN) CFO Relocates to U.S. to Drive Growth
Smith & Nephew CFO shifts base to U.S. from U.K.
Smith & Nephew (SNN) Upgraded to Buy: What Does It Mean for the Stock?
Smith & Nephew (SNN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Smith+Nephew (SNN) Highlights Advances in REGENETEN Implant Technology
Smith+Nephew (SNN) Highlights Advances in REGENETEN Implant Technology
Smith+Nephew unveils major clinical evidence and patient access updates for its REGENETEN™ Bioinductive Implant
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces new evidence and market updates that highlight the clinical performance of its REGENETEN Bioinductive Implant an...
What Does the Market Think About Smith & Nephew?
Smith & Nephew's (NYSE: SNN) short percent of float has risen 6.56% since its last report. The company recently reported that it has 2.84 million shares sold short , which is 0.65% of all regular sha...
Smith+Nephew extends Advanced Wound Bioactives portfolio with US launch of CENTRIO Platelet-Rich-Plasma System
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the launch of the CENTRIO Platelet-Rich-Plasma (PRP) System, a biodynamic hematogel derived from a patient's own...
Smith & Nephew: Doing Better And Still Offers Value
Smith & Nephew shows solid growth with rising revenue, resumed dividends, and confidence-driven buybacks. Click here to read my recent SNN stock analysis.
Smith & Nephew plc 2025 Q2 - Results - Earnings Call Presentation
Smith & Nephew plc (SNN) Q2 2025 Earnings Call Transcript
Top 2 Health Care Stocks You May Want To Dump In Q3
As of Aug. 5, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Smith & Nephew Non-GAAP EPS of $0.43, revenue of $2.96B; reaffirms FY outlook
Smith & Nephew press release (SNN): 1H Non-GAAP EPSA of $0.43. Revenue of $2.96B (+4.6% Y/Y). H1 underlying revenue growth was 5.0%.
FTSE Opens Higher as Smith & Nephew Rallies on Strong Results
FTSE climbs as Smith & Nephew jumps on earnings beat, but Domino’s sinks after guidance cut. The post FTSE Opens Higher as Smith & Nephew Rallies on Strong Results appeared first on Investomania .
Advanced Wound Care Market to Hit $19.32 Billion by 2030 – What's Fueling the Surge? | MarketsandMarkets™.
Delray Beach, FL, July 30, 2025 (GLOBE NEWSWIRE) -- The global Advanced Wound Care Market , valued at US$12.48 billion in 2024 stood at US$13.37 billion in 2025 and is projected to advance at a resili...
Smith & Nephew: Investors Looking To Continued Innovation And Margin Growth In Q2 Earnings
Smith+Nephew expands market-leading fixation strength of Q-FIX™ All-Suture Anchor portfolio with new knotless option
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces the release of its Q-FIX KNOTLESS All-Suture Anchor for soft tissue-to-bone fixation indications across multiple joint...
Martin Cobb's Past Picks: Saputo, Smith & Nephew & Electronic Arts
Martin Cobb, Senior Vice-President and Equities at Lorne Steinberg Wealth Management, discusses his past stock picks and how they're doing in the market today.
Smith and Nephew Share Price
Smith & Nephew is an international medical technology business that has a focus on orthopaedics, sports medicine, and high-performance wound management. Its innovative products ensure steady demand, m...
Smith+Nephew's new TRIGEN™ MAX Tibia Nailing System brings ‘next-level nailing' to trauma surgeons repairing tibial fractures
The future of fracture fixation with novel side-specific nails featuring variable angle locking technology Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the l...
Ajay Dhankhar joins Smith+Nephew as Chief Corporate Development & Strategy Officer
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces the appointment of Ajay Dhankhar, PhD, as Chief Corporate Development & Strategy Officer, effective today. Ajay will r...
Smith+Nephew and Standard Health partner on first Orthopaedic Ambulatory Surgery Centre in the UK
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces a strategic partnership with Standard Health www.standardhealth.co.uk to support the development of the first-ev...